|
GlaxoSmithKline Consumer Healthcare Ltd records strong growth for the year ended December 31, 2010
? Sales rise by 20 % and Profits up by 29 % Recommend a total Dividend of Rs. 50 per equity share of Rs. 10 each
Highlights for the quarter______________________________________________________
Healthy growth across portfolio in Q4
Q4 closed with a stellar performance of 21 % growth in sales and 58 % in profits
Unique and differentiated product innovations, maintained distribution and cost reduction drive overall growth
Recommended a Divided of Rs. 50 /- per equity share of Rs. 10 each (Dividend of Rs. 25 per equity share and a Special Dividend of Rs. 25 per equity share to celebrate Golden Jubilee of the Company) for the year ended December 31, 2010
Overview________________________________________________________________________________
GlaxoSmithKline Consumer Healthcare Limited (GSKCH) today declared its financial results for the year ended December 31, 2010. Net sales at Rs 2306 Crores recorded an impressive growth of 20% over 2009 with PAT at Rs. 300 Crores growing by 29 % for the same period and PBT at Rs 452 Crores growing by 28 %. For the fourth quarter, net sales were Rs. 508 crores while PBT and PAT were Rs 80 Crores and Rs 53 Crores respectively.
The Board of Directors of the Company also recommended a Dividend at the rate of Rs. 50 per equity share of Rs. 10 each (Dividend of Rs. 25 per equity share and a Special Dividend of Rs. 25 per equity share to celebrate Golden Jubilee of the Company) for the year ended December 31, 2010.
"2010 was an exciting year for the FMCG industry with robust growth and expansion of various new categories. Commenting on the results,Mr. Zubair
Ahmed, Managing Director, GlaxoSmithKline
Consumer Healthcare Ltd.said, "2010 has been a testimony to the customer confidence and faith in our brands. Realising the ever changing consumer needs, we launched a slew of new products that reiterates GSKCH's commitment and focus on growth through customer-driven innovations. We will continue the growth impetus of our Consumer Healthcare business and maintain our investments to build on our brands while we constantly innovate to meet the ever changing needs of our consumers."
The year saw the introduction of new brands into India from GSK's global portfolio as well as transformation of the entire product line for Horlicks- GSKCH's flagship brand.
___________________________________________________________________________________________________________________________
About GlaxoSmithKline Consumer Healthcare
Ltd.
GSKCH is an associate of GlaxoSmithKline plc. of U.K, a global science based healthcare company. GSKCH has continually benefited from the technical and marketing inputs that have been available as a consequence of this association. GSKCH is the largest player in the health food drinks industry. The Company with its manufacturing plants located in Nabha, Rajahmundry and Sonepat has a total workforce of about 2900 people.
GSKCH has a strong marketing and distribution network in India comprising over 550 wholesalers and direct coverage of over 6,40,000 retail outlets. Its flagship product, Horlicks, is a widely regarded and highly respected brand for over 100 years. The Company also manufactures and markets Boost, Viva and Maltova and in addition markets and distributes a number of products in diverse categories, which include prominent names such as Eno, Crocin, and Iodex as well as products from the global portfolio like Breathe Right and Sensodyne.
Media Contacts ______________________________________________________
Sophia Christina
Genesis Burson Marsteller
sophia.christina@bm.com+91 9999161478
Sakshi Mathur
Genesis Burson Marsteller
sakshi.mathur@bm.com+91 9999007585
Kuheli Ray
Genesis Burson Marsteller
kuheli.ray@bm.com+91 9999783541
|
